COPD Guidelines and Homecare

Study Results – Sanofi and Regeneron Make Advance in COPD Research

Regeneron Pharmaceuticals and Sanofi have announced positive results from their phase 3 trial, titled NOTUS, evaluating Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD). The trial demonstrated that Dupixent significantly reduced COPD exacerbations by 34% (compared to placebo) in patients with moderate-to-severe COPD who also show evidence of type 2 inflammation of

RSV

JoinAStudy Investigator Dr. Anil Gupta Dispels Myths Around RSV

In a recent podcast, “Dispelling the Myth that RSV is Only a Disease of Childhood,” Dr. Anil Gupta and colleagues tackle a widely held misconception about Respiratory Syncytial Virus (RSV): that it’s solely a disease of childhood. While RSV is well-known for causing respiratory infections in infants and young children, it’s time to shed light on

New Study Results Published – Lilly GZGI

Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,

globalization clinical trials

The Globalization of Clinical Trials

Clinical research, like many industries, has become increasingly globalized during the 21st century. Emerging markets in Asia and South America offer access to diverse patient populations, a greater number of subjects for recruitment, more opportunity for global collaboration and increased inclusivity. The globalization of clinical trials reflects a dynamic and interconnected approach to advancing medical

FDA Approves World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

The US Food and Drug Administration (FDA) has granted approval to GlaxoSmithKline (GSK) for Arexvy, the world’s first vaccine designed to protect older adults against respiratory syncytial virus (RSV). RSV is a common respiratory virus that can cause serious illness, particularly in adults over 65 years of age, and in infants and young children. It